Summary

The pen needles market is projected to reach USD 3.08 Billion by 2030 from USD 1.81 Billion in 2024 at a CAGR of 9.2% during the forecast period. The elderly are susceptible, due to their age, to insulin resistance, a decrease in pancreatic function, and other comorbid conditions, including hypertension and obesity, which raise the risk of developing diabetes. As people age, the body becomes less responsive to insulin's role in regulating blood sugar, hence increasing the chances of developing Type 2 diabetes. In addition, the reduction in physical activity among older adults, coupled with lifestyle changes, contributes to rising trends of the condition. The increasing incidence rate of diabetes with age has simple direct implications concerning the increased desire for insulin administration devices, especially the pen needles. Insulin injections are an essential component of diabetes management among elderly patients, especially patients with Type 1 or advanced Type 2 diabetes. Ease of use, convenience, and reduced pain compared to traditional syringes make the pen needle particularly suitable for older adults. Other conditions most of the elderly suffer from include arthritis, which could primarily hinder them using syringes, hence developing the preference for insulin pens that use pen needles.

“The standard pen needles segment is accounted for the largest share of global pen needles market.”
The market share of pen needles in the global market is dominated by the standard ones because of their wide compatibility with most of the pen injectors used for insulin administration and other injectable drugs. These needles are developed to be able to fit in a variety of insulin pens, making them available to patients across all demographics.Their simplicity and affordability make them popular, and their ease of use is something that is found in regions whose populations are rather cost-sensitive. Standard pen needles are also apt for Type 1 and Type 2 diabetes patients. Other patients also require injectable medications for some other conditions; hence, standard pen needles find wide usage in all these conditions, making the patients and their healthcare providers retain them as a first choice for their use.




“Online purchase segment will grow at the highest CAGR during the forecast period of the global pen needles market.”
The online purchase segment of the global pen needles market is expected to have the highest growth rate during the forecast period due to the benefits and convenience that e-commerce platforms have provided. For instance, the websites provide competitive prices and, sometimes, offer discounts, promotional offers, and bundle deals that can make the purchase of pen needles cheaper for customers. Apart from this, the appeal of online shopping is greater than traditional retail shops due to more ease in product comparison, reading customer reviews, and availability of a comprehensive range of products and sizes. The availability on online platforms also increases the accessibility for customers located at remote locations or those with some mobility issues since they can receive their pen needles at home. E-commerce adoption, with more convenience and cost-effectiveness, ensures that the segment of online purchases is going to grow strongly.

“North America to witness the substantial growth rate during the forecast period.”
The pen needles market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2024, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the pen needles market in 2024. This is largely because of the health care systems that are advanced to facilitate better access to diabetes care. The U.S. and Canada have a well-developed medical infrastructure, making it easy for patients to reach pen needles for insulin delivery devices. Furthermore, with millions of people suffering from diabetes in these regions, there is high demand for effective, as well as user-friendly, delivery solutions. Pen needles are popular for their convenience, ease of use, and minimal discomfort. It is the preferred way to manage Type 1 and Type 2 diabetes. With extensive healthcare coverage, a high patient awareness level, and a large diabetic population, North America is the most significant market for pen needles.





A breakdown of the primary participants (supply-side) for the pen needles market referred to for this report is provided below:
• By Company Type: Tier 1–22%, Tier 2–36%, and Tier 3–42%
• By Designation: C-level–23%, Director Level–28%, and Others–49%
• By Region: North America–38%, Europe–29%, Asia Pacific–23%, Latin America- 6%, and Middle East and Africa– 1% and GCC Countries– 3%
Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US).
Research Coverage:
The market study covers the pen needles market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by type, length, application, mode of purchase, setting and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.


This report provides insights on:
 Analysis of Market Dynamics: Drivers (rising incidence of chronic diseases, favorable reimbursements in certain countries, and decreasing prices of insulin formulations) restraints (rising pet care costs, poor reimbursement scenario in emerging countries, and needle anxiety) opportunities (growing preference for biosimilar drugs, emerging economies to offer high-growth potential, and rising healthcare expenditure on diabetes), and challenges (implementation of regulations for safety pen needles, reuse of pen needles, and misuse of injection pens)
 Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the pen needles market.
 Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
 Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the pen needles market.
 Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the pen needles market like Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), and Terumo Corporation (Japan).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.2.2 MARKET SEGMENTATION 26
1.2.3 YEARS CONSIDERED 27
1.2.4 CURRENCY CONSIDERED 27
1.3 LIMITATIONS 28
1.4 STAKEHOLDERS 28
1.5 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY DATA 30
2.1.1.1 Key data from secondary sources 31
2.1.2 PRIMARY DATA 32
2.1.2.1 Key data from primary sources 33
2.1.2.2 Key industry insights 34
2.2 MARKET SIZE ESTIMATION 36
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 42
2.4 MARKET SHARE ANALYSIS 43
2.5 METHODOLOGY-RELATED LIMITATIONS 43
2.6 STUDY ASSUMPTIONS 43
2.7 RISK ASSESSMENT 44
3 EXECUTIVE SUMMARY 45
4 PREMIUM INSIGHTS 49
4.1 PEN NEEDLES MARKET OVERVIEW 49
4.2 ASIA PACIFIC: PEN NEEDLES MARKET, BY LENGTH AND COUNTRY (2024) 50
4.3 GEOGRAPHIC GROWTH OPPORTUNITIES 51
4.4 REGIONAL MIX 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
5.2.1 DRIVERS 53
5.2.1.1 Rising incidence of chronic diseases 53
5.2.1.2 Favorable reimbursements in certain countries 54
5.2.1.3 Growing adoption of self-administration 54
5.2.1.4 Decreasing prices of insulin formulations 55
5.2.2 RESTRAINTS 56
5.2.2.1 Alternative methods of drug delivery 56
5.2.2.2 Poor reimbursement scenario in emerging markets 56
5.2.2.3 Needle anxiety 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Growing preference for biosimilar drugs 57
5.2.3.2 Emerging economies to offer high-growth potential 57
5.2.3.3 Rising healthcare expenditure on diabetes 57
5.2.3.4 Implementation of regulations for safety pen needles 58
5.2.4 CHALLENGES 58
5.2.4.1 Reuse of pen needles 58
5.2.4.2 Misuse of injection pens 59
5.3 INDUSTRY TRENDS 59
5.3.1 GROWING PREFERENCE FOR SAFETY-ENGINEERED PEN NEEDLES 59
5.3.2 RISING ADOPTION OF SHORTER AND ULTRA-THIN NEEDLES 60
5.4 REIMBURSEMENT SCENARIO 61
5.5 PRICING ANALYSIS 62
5.5.1 INDICATIVE SELLING PRICE OF PEN NEEDLES, BY KEY PLAYER, 2024 62
5.5.2 AVERAGE SELLING PRICE TREND OF STANDARD PEN NEEDLES,
BY REGION, 2022–2024 64
5.6 VALUE CHAIN ANALYSIS 64
5.7 ECOSYSTEM ANALYSIS 65
5.8 PORTER’S FIVE FORCES ANALYSIS 67
5.8.1 INTENSITY OF COMPETITIVE RIVALRY 68
5.8.2 BARGAINING POWER OF SUPPLIERS 68
5.8.3 BARGAINING POWER OF BUYERS 69
5.8.4 THREAT OF SUBSTITUTES 69
5.8.5 THREAT OF NEW ENTRANTS 69
5.9 SUPPLY CHAIN ANALYSIS 70
5.10 REGULATORY ANALYSIS 71
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.10.2 REGULATORY FRAMEWORK 75
5.10.2.1 North America 75
5.10.2.1.1 US 75
5.10.2.1.2 Canada 75
5.10.2.2 Europe 77
5.10.2.3 Asia Pacific 77
5.10.2.3.1 Japan 77
5.10.2.3.2 China 78
5.10.2.3.3 India 79
5.11 TRADE ANALYSIS 80
5.11.1 TRADE ANALYSIS OF NEEDLES, CATHETERS, AND CANNULAE USED IN MEDICAL, SURGICAL, DENTAL, OR VETERINARY SCIENCES
(HS CODE 901839) 80
5.11.2 EXPORT DATA (HS CODE 901839), 2019–2023 80
5.11.3 IMPORT DATA (HS CODE 901839), 2019–2023 81
5.12 PATENT ANALYSIS 81
5.12.1 PATENT PUBLICATION TRENDS FOR PEN NEEDLES 81
5.12.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 82
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 85
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 85
5.13.2 BUYING CRITERIA 86
5.14 CASE STUDY ANALYSIS 87
5.14.1 CASE STUDY 1: IMPACT OF CCG-WIDE INSULIN PEN NEEDLE 87
5.14.2 CASE STUDY 2: PEN NEEDLE DESIGN INFLUENCES EASE INSERTION,
PAIN, AND SKIN TRAUMA IN SUBJECTS WITH TYPE 2 DIABETES 88
5.14.3 CASE STUDY 3: DROPSAFE SAFETY PEN NEEDLE HELPS TO PREVENT ACCIDENTAL NEEDLESTICKS AFTER INJECTIONS 89
5.15 TECHNOLOGY ANALYSIS 89
5.15.1 KEY TECHNOLOGIES 89
5.15.1.1 Fluid flow enhancement technology 89
5.15.1.2 Ultra-thin needle technology 90
5.15.2 COMPLEMENTARY TECHNOLOGIES 90
5.15.2.1 Microfabricated needles 90
5.15.2.2 AI in pen injectors 90
5.15.3 ADJACENT TECHNOLOGIES 91
5.15.3.1 Autoinjectors 91
5.16 KEY CONFERENCES & EVENTS, 2025–2026 92
5.17 ADJACENT MARKET ANALYSIS 93
5.17.1 AUTOINJECTORS MARKET 93
5.17.2 INSULIN DELIVERY DEVICES MARKET 95
5.17.3 INJECTION PENS MARKET 96
5.17.4 NEEDLES MARKET 97
5.18 IMPACT OF AI/GEN AI ON PEN NEEDLES MARKET 97
5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 98
5.20 UNMET NEEDS ANALYSIS 99
5.21 INVESTMENT & FUNDING SCENARIO 100

6 PEN NEEDLES MARKET, BY TYPE 102
6.1 INTRODUCTION 103
6.2 STANDARD PEN NEEDLES 103
6.2.1 GREATER PREFERENCE AND AFFORDABILITY OF STANDARD PEN NEEDLES TO SUPPORT GROWTH 103
6.3 SAFETY PEN NEEDLES 106
6.3.1 GROWING CONCERNS OVER NEEDLESTICK INJURIES TO DRIVE ADOPTION OF SAFETY PEN NEEDLES 106
7 PEN NEEDLES MARKET, BY LENGTH 108
7.1 INTRODUCTION 109
7.2 8MM 110
7.2.1 WIDE ADOPTION IN NORTH AMERICA TO BOOST MARKET GROWTH 110
7.3 5MM 112
7.3.1 SHORTER LENGTH AND LOW PAIN TO FUEL UPTAKE 112
7.4 6MM 114
7.4.1 FAVORABLE REIMBURSEMENTS TO BOOST DEMAND 114
7.5 4MM 116
7.5.1 WIDE ADOPTION IN PEDIATRIC INSULIN DELIVERY TO DRIVE DEMAND 116
7.6 12MM 118
7.6.1 HIGH UTILIZATION OF SHORTER NEEDLES TO LIMIT ADOPTION 118
7.7 10MM 120
7.7.1 PAINFUL PROCEDURES TO RESTRAIN ADOPTION 120
8 PEN NEEDLES MARKET, BY APPLICATION 122
8.1 INTRODUCTION 123
8.2 INSULIN THERAPY 123
8.2.1 RISING INCIDENCE OF DIABETES TO PROPEL MARKET 123
8.3 GLUCAGON-LIKE PEPTIDE-1 THERAPY 125
8.3.1 GROWING FOCUS OF PHARMA COMPANIES ON GLP-1 DRUG DEVELOPMENT TO DRIVE MARKET 125
8.4 GROWTH HORMONE THERAPY 126
8.4.1 AVAILABILITY OF LONG-ACTING TREATMENTS TO AFFECT DEMAND FOR NEEDLES 126
8.5 OSTEOPOROSIS 128
8.5.1 RISING VITAMIN D DEFICIENCY CASES TO PROPEL MARKET 128
8.6 OTHER APPLICATIONS 129
9 PEN NEEDLES MARKET, BY MODE OF PURCHASE 131
9.1 INTRODUCTION 132
9.2 PRESCRIPTION-BASED PURCHASE 132
9.2.1 RETAIL PURCHASES TO SUPPORT MARKET GROWTH 132

9.3 OTC PURCHASES 133
9.3.1 DISCOUNTS OFFERED BY LOCAL PHARMACIES, SUPPLIERS, AND DISTRIBUTORS TO DRIVE MARKET 133
9.4 ONLINE PURCHASE 134
9.4.1 CONVENIENCE AND TIME-EFFICIENT BENEFITS TO PROPEL MARKET 134
9.5 OTHER MODES OF PURCHASE 135
10 PEN NEEDLES MARKET, BY CARE SETTING 138
10.1 INTRODUCTION 139
10.2 HOME CARE SETTINGS 139
10.2.1 GROWING PREFERENCE FOR SELF-ADMINISTRATION OF INSULIN TO PROPEL MARKET 139
10.3 HOSPITALS & CLINICS 140
10.3.1 INCREASING ADOPTION OF SAFETY PEN NEEDLES TO DRIVE MARKET 140
10.4 OTHER CARE SETTINGS 142
11 PEN NEEDLES MARKET, BY REGION 143
11.1 INTRODUCTION 144
11.2 NORTH AMERICA 144
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 144
11.2.2 US 148
11.2.2.1 Increasing burden of diabetes to contribute to growth 148
11.2.3 CANADA 151
11.2.3.1 Growing initiatives for diabetic coverage to drive market 151
11.3 EUROPE 154
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 154
11.3.2 GERMANY 157
11.3.2.1 Advanced healthcare system to intensify growth 157
11.3.3 UK 160
11.3.3.1 High incidence of cardiovascular disease to favor growth 160
11.3.4 FRANCE 163
11.3.4.1 Growing delivery of insulin devices to propel market 163
11.3.5 ITALY 166
11.3.5.1 Low product pricing to support growth 166
11.3.6 SPAIN 168
11.3.6.1 Supportive regulations mandating the use of safety pen needles to propel market 168
11.3.7 REST OF EUROPE 171
11.4 ASIA PACIFIC 173
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 173
11.4.2 JAPAN 178
11.4.2.1 Growing inclination toward public health insurance to boost market 178

11.4.3 CHINA 180
11.4.3.1 Rising focus on modernizing healthcare to expedite growth 180
11.4.4 AUSTRALIA & NEW ZEALAND 183
11.4.4.1 Increasing rate of chronic diseases to amplify growth 183
11.4.5 INDIA 185
11.4.5.1 Growing per capita income to fuel market 185
11.4.6 SOUTH KOREA 187
11.4.6.1 Increasing geriatric population to facilitate growth 187
11.4.7 SOUTHEAST ASIA 190
11.4.7.1 Booming medical tourism industry to drive market 190
11.4.8 REST OF ASIA PACIFIC 193
11.5 LATIN AMERICA 195
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 195
11.5.2 BRAZIL 197
11.5.2.1 Growing incidence of non-communicable diseases to drive market 197
11.5.3 MEXICO 200
11.5.3.1 Universal health coverage to stimulate growth 200
11.5.4 ARGENTINA 202
11.5.4.1 Increasing obesity rates to bolster growth 202
11.5.5 REST OF LATIN AMERICA 205
11.6 MIDDLE EAST & AFRICA 207
11.6.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO AUGMENT GROWTH 207
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 207
11.7 GCC COUNTRIES 209
11.7.1 HIGHER DISPOSABLE INCOME TO ENCOURAGE GROWTH 209
11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 210
12 COMPETITIVE LANDSCAPE 213
12.1 INTRODUCTION 213
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 213
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PEN NEEDLES MARKET 214
12.3 REVENUE ANALYSIS, 2019–2023 215
12.4 MARKET SHARE ANALYSIS, 2023 215
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 217
12.5.1 STARS 217
12.5.2 EMERGING LEADERS 217
12.5.3 PERVASIVE PLAYERS 217
12.5.4 PARTICIPANTS 218
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 219
12.5.5.1 Company footprint 219
12.5.5.2 Region footprint 220
12.5.5.3 Type footprint 221
12.5.5.4 Length footprint 222
12.5.5.5 Application footprint 223
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 224
12.6.1 PROGRESSIVE COMPANIES 224
12.6.2 RESPONSIVE COMPANIES 224
12.6.3 DYNAMIC COMPANIES 224
12.6.4 STARTING BLOCKS 224
12.6.5 COMPETITIVE BENCHMARKING 226
12.6.5.1 Detailed list of key startups/SMEs 226
12.6.5.2 Competitive benchmarking of key startups/SMEs 227
12.7 COMPANY VALUATION & FINANCIAL METRICS 227
12.8 COMPETITIVE SCENARIO 229
12.8.1 PRODUCT LAUNCHES & APPROVALS 229
12.8.2 DEALS 229
12.8.3 EXPANSIONS 230
12.9 BRAND/PRODUCT COMPARISON 231
12.10 R&D EXPENDITURE OF KEY PLAYERS 232
13 COMPANY PROFILES 233
13.1 KEY PLAYERS 233
13.1.1 EMBECTA CORP. 233
13.1.1.1 Business overview 233
13.1.1.2 Products offered 234
13.1.1.3 Recent developments 235
13.1.1.3.1 Deals 235
13.1.1.3.2 Expansions 235
13.1.1.3.3 Other developments 236
13.1.1.4 MnM view 236
13.1.1.4.1 Right to win 236
13.1.1.4.2 Strategic choices 236
13.1.1.4.3 Weaknesses & competitive threats 236
13.1.2 NOVO NORDISK A/S 237
13.1.2.1 Business overview 237
13.1.2.2 Products offered 238
13.1.2.3 Recent developments 239
13.1.2.3.1 Expansions 239
13.1.2.4 MnM view 239
13.1.2.4.1 Right to win 239
13.1.2.4.2 Strategic choices 239
13.1.2.4.3 Weaknesses & competitive threats 239

13.1.3 B. BRAUN SE 240
13.1.3.1 Business overview 240
13.1.3.2 Products offered 241
13.1.3.3 MnM view 242
13.1.3.3.1 Right to win 242
13.1.3.3.2 Strategic choices 242
13.1.3.3.3 Weaknesses & competitive threats 242
13.1.4 YPSOMED 243
13.1.4.1 Business overview 243
13.1.4.2 Products offered 245
13.1.4.3 Recent developments 245
13.1.4.3.1 Deals 245
13.1.4.4 MnM view 246
13.1.4.4.1 Right to win 246
13.1.4.4.2 Strategic choices 246
13.1.4.4.3 Weaknesses & competitive threats 246
13.1.5 TERUMO CORPORATION 247
13.1.5.1 Business overview 247
13.1.5.2 Products offered 248
13.1.5.3 MnM view 249
13.1.5.3.1 Right to win 249
13.1.5.3.2 Strategic choices 249
13.1.5.3.3 Weaknesses & competitive threats 249
13.1.6 NIPRO 250
13.1.6.1 Business overview 250
13.1.6.2 Products offered 251
13.1.6.3 Recent developments 252
13.1.6.3.1 Expansions 252
13.1.7 OWEN MUMFORD 254
13.1.7.1 Business overview 254
13.1.7.2 Products offered 254
13.1.7.3 Recent developments 255
13.1.7.3.1 Deals 255
13.1.8 ARKRAY, INC. 256
13.1.8.1 Business overview 256
13.1.8.2 Products offered 256
13.1.8.3 Recent developments 257
13.1.8.3.1 Expansions 257
13.1.9 ULTIMED, INC. 258
13.1.9.1 Business overview 258
13.1.9.2 Products offered 258
13.1.9.3 Recent developments 259
13.1.9.3.1 Product launches 259
13.1.10 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD. 260
13.1.10.1 Business overview 260
13.1.10.2 Products offered 260
13.1.11 MONTMÉD 261
13.1.11.1 Business overview 261
13.1.11.2 Products offered 261
13.1.11.3 Recent developments 261
13.1.11.3.1 Product approvals 261
13.1.11.3.2 Deals 262
13.1.12 HTL-STREFA 263
13.1.12.1 Business overview 263
13.1.12.2 Products offered 263
13.1.13 ALLISON MEDICAL, INC. 265
13.1.13.1 Business overview 265
13.1.13.2 Products offered 265
13.1.14 GLUCORX LIMITED 266
13.1.14.1 Business overview 266
13.1.14.2 Products offered 266
13.1.15 BERPU MEDICAL TECHNOLOGY CO., LTD. 267
13.1.15.1 Business overview 267
13.1.15.2 Products offered 267
13.2 OTHER PLAYERS 268
13.2.1 VAN HEEK MEDICAL 268
13.2.2 SIMPLE DIAGNOSTICS 269
13.2.3 IYON HEALTH MEDICAL 270
13.2.4 LINKS MEDICAL PRODUCTS INC. 271
13.2.5 MHC MEDICAL PRODUCTS, LLC 271
13.2.6 ADVACARE PHARMA 272
13.2.7 ARTSANA S.P.A. 273
13.2.8 PROMISEMED MEDICAL DEVICES, INC. 274
13.2.9 TRIVIDIA HEALTH, INC. 275
13.2.10 VOGT MEDICAL VERTRIEB GMBH 276
14 APPENDIX 277
14.1 DISCUSSION GUIDE 277
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 282
14.3 CUSTOMIZATION OPTIONS 284
14.4 RELATED REPORTS 284
14.5 AUTHOR DETAILS 285